Gilead Sciences Inc. (GILD)

$67.72

-0.14

(-0.21%)▲

Market is closed - opens 7 PM, 20 May 2024
star icon

Gilead Sciences, Inc. is a biopharmaceutical company that develops innovative treatments for life-threatening diseases.

Insights on Gilead Sciences Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 7.11B → 6.68B (in $), with an average decrease of 6.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 2.18B → -4.17B (in $), with an average decrease of 213.1% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 75.8% return, outperforming this stock by 89.2%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 295.6% return, outperforming this stock by 297.2%

Performance

  • $67.23
    $67.77
    $67.72
    downward going graph

    0.72%

    Downside

    Day's Volatility :0.8%

    Upside

    0.07%

    downward going graph
  • $64.33
    $86.09
    $67.72
    downward going graph

    5.01%

    Downside

    52 Weeks Volatility :25.28%

    Upside

    21.34%

    downward going graph

Returns

PeriodGilead Sciences Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
-6.0%
0.5%
5.8%
6 Months
-10.89%
14.1%
18.1%
1 Year
-13.41%
11.9%
31.5%
3 Years
-1.64%
18.7%
25.4%

Highlights

Market Capitalization
84.5B
Book Value
$14.08
Dividend Share
3.02
Dividend Yield
4.54%
Earnings Per Share (EPS)
0.36
PE Ratio
188.5
PEG Ratio
0.42
Wall Street Target Price
81.29
Profit Margin
1.77%
Operating Margin TTM
34.43%
Return On Assets TTM
10.5%
Return On Equity TTM
2.39%
Revenue TTM
27.4B
Revenue Per Share TTM
22.0
Quarterly Revenue Growth YOY
5.3%
Gross Profit TTM
21.6B
EBITDA
12.7B
Diluted Eps TTM
0.36
Quarterly Earnings Growth YOY
-0.13
EPS Estimate Current Year
3.75
EPS Estimate Next Year
7.15
EPS Estimate Current Quarter
-1.51
EPS Estimate Next Quarter
1.69

Analyst Recommendation

Buy
    52%Buy
    44%Hold
    2%Sell
Based on 36 Wall street analysts offering stock ratings for Gilead Sciences Inc.(by analysts ranked 0 to 5 stars)
Based on 36 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
19
19
18
Hold
16
16
19
Sell
1
1
00

Analyst Forecast

What analysts predicted

Upside of 20.04%

Current $67.72
Target $81.29

Company Financials

FY18Y/Y Change
Revenue
22.1B
↓ 15.24%
Net Income
5.5B
↑ 17.87%
Net Profit Margin
24.65%
↑ 6.92%
FY19Y/Y Change
Revenue
22.4B
↑ 1.46%
Net Income
5.4B
↓ 1.26%
Net Profit Margin
23.99%
↓ 0.66%
FY20Y/Y Change
Revenue
24.7B
↑ 9.98%
Net Income
89.0M
↓ 98.35%
Net Profit Margin
0.36%
↓ 23.63%
FY21Y/Y Change
Revenue
27.3B
↑ 10.6%
Net Income
6.2B
↑ 6894.38%
Net Profit Margin
22.8%
↑ 22.44%
FY22Y/Y Change
Revenue
27.3B
↓ 0.09%
Net Income
4.6B
↓ 26.23%
Net Profit Margin
16.83%
↓ 5.97%
FY23Y/Y Change
Revenue
27.1B
↓ 0.6%
Net Income
5.7B
↑ 23.37%
Net Profit Margin
20.89%
↑ 4.06%
Q4 FY22Q/Q Change
Revenue
7.4B
↑ 4.93%
Net Income
1.6B
↓ 8.33%
Net Profit Margin
22.2%
↓ 3.2%
Q1 FY23Q/Q Change
Revenue
6.4B
↓ 14.03%
Net Income
1.0B
↓ 38.41%
Net Profit Margin
15.9%
↓ 6.3%
Q2 FY23Q/Q Change
Revenue
6.6B
↑ 3.89%
Net Income
1.0B
↑ 3.47%
Net Profit Margin
15.84%
↓ 0.06%
Q3 FY23Q/Q Change
Revenue
7.1B
↑ 6.83%
Net Income
2.2B
↑ 108.61%
Net Profit Margin
30.92%
↑ 15.08%
Q4 FY23Q/Q Change
Revenue
7.1B
↑ 0.92%
Net Income
1.4B
↓ 34.45%
Net Profit Margin
20.08%
↓ 10.84%
Q1 FY24Q/Q Change
Revenue
6.7B
↓ 6.03%
Net Income
-4.2B
↓ 391.81%
Net Profit Margin
-62.37%
↓ 82.45%
FY18Y/Y Change
Total Assets
63.7B
↓ 9.4%
Total Liabilities
42.1B
↓ 15.35%
FY19Y/Y Change
Total Assets
61.6B
↓ 3.22%
Total Liabilities
39.0B
↓ 7.51%
FY20Y/Y Change
Total Assets
68.4B
↑ 11.0%
Total Liabilities
50.2B
↑ 28.76%
FY21Y/Y Change
Total Assets
68.0B
↓ 0.67%
Total Liabilities
46.9B
↓ 6.57%
FY22Y/Y Change
Total Assets
63.2B
↓ 7.04%
Total Liabilities
42.0B
↓ 10.51%
FY23Y/Y Change
Total Assets
62.1B
↓ 1.66%
Total Liabilities
39.4B
↓ 6.16%
Q4 FY22Q/Q Change
Total Assets
63.2B
↑ 0.98%
Total Liabilities
42.0B
↑ 1.11%
Q1 FY23Q/Q Change
Total Assets
61.9B
↓ 2.05%
Total Liabilities
40.9B
↓ 2.44%
Q2 FY23Q/Q Change
Total Assets
62.3B
↑ 0.75%
Total Liabilities
41.2B
↑ 0.75%
Q3 FY23Q/Q Change
Total Assets
62.4B
↑ 0.06%
Total Liabilities
40.1B
↓ 2.7%
Q4 FY23Q/Q Change
Total Assets
62.1B
↓ 0.4%
Total Liabilities
39.4B
↓ 1.88%
Q1 FY24Q/Q Change
Total Assets
56.3B
↓ 9.39%
Total Liabilities
38.8B
↓ 1.37%
FY18Y/Y Change
Operating Cash Flow
8.4B
↓ 29.4%
Investing Cash Flow
14.4B
↓ 189.33%
Financing Cash Flow
-12.3B
↓ 463.04%
FY19Y/Y Change
Operating Cash Flow
9.1B
↑ 8.86%
Investing Cash Flow
-7.8B
↓ 154.45%
Financing Cash Flow
-7.6B
↓ 38.03%
FY20Y/Y Change
Operating Cash Flow
8.2B
↓ 10.67%
Investing Cash Flow
-14.6B
↑ 86.96%
Financing Cash Flow
770.0M
↓ 110.09%
FY21Y/Y Change
Operating Cash Flow
11.4B
↑ 39.37%
Investing Cash Flow
-3.1B
↓ 78.58%
Financing Cash Flow
-8.9B
↓ 1252.86%
FY22Y/Y Change
Operating Cash Flow
9.1B
↓ 20.31%
Investing Cash Flow
-2.5B
↓ 21.24%
Financing Cash Flow
-6.5B
↓ 27.13%
FY23Y/Y Change
Operating Cash Flow
8.0B
↓ 11.75%
Investing Cash Flow
-2.3B
↓ 8.15%
Financing Cash Flow
-5.1B
↓ 20.78%
Q4 FY22Q/Q Change
Operating Cash Flow
2.6B
↓ 10.37%
Investing Cash Flow
-375.0M
↓ 47.41%
Financing Cash Flow
-1.6B
↓ 26.63%
Q1 FY23Q/Q Change
Operating Cash Flow
1.7B
↓ 32.03%
Investing Cash Flow
-826.0M
↑ 120.27%
Financing Cash Flow
-1.4B
↓ 9.52%
Q2 FY23Q/Q Change
Operating Cash Flow
2.3B
↑ 34.0%
Investing Cash Flow
-483.0M
↓ 41.53%
Financing Cash Flow
-1.1B
↓ 21.69%
Q3 FY23Q/Q Change
Operating Cash Flow
1.8B
↓ 24.86%
Investing Cash Flow
-229.0M
↓ 52.59%
Financing Cash Flow
-1.5B
↑ 37.87%
Q4 FY23Q/Q Change
Operating Cash Flow
2.2B
↑ 23.52%
Investing Cash Flow
-727.0M
↑ 217.47%
Financing Cash Flow
-1.1B
↓ 27.6%

Technicals Summary

Sell

Neutral

Buy

Gilead Sciences Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Gilead Sciences Inc.
Gilead Sciences Inc.
2.36%
-10.89%
-13.41%
-1.64%
2.82%
Eli Lilly And Company
Eli Lilly And Company
3.22%
28.85%
75.84%
295.62%
562.48%
Johnson & Johnson
Johnson & Johnson
6.11%
3.16%
-2.42%
-9.28%
11.72%
Merck & Co. Inc.
Merck & Co. Inc.
4.76%
27.77%
15.08%
65.27%
66.32%
Abbvie Inc
Abbvie Inc
1.07%
20.32%
16.02%
41.98%
108.49%
Amgen Inc.
Amgen Inc.
18.92%
17.76%
39.35%
24.56%
85.56%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Gilead Sciences Inc.
Gilead Sciences Inc.
188.5
188.5
0.42
3.75
0.02
0.11
0.05
14.08
Eli Lilly And Company
Eli Lilly And Company
113.57
113.57
1.43
13.79
0.51
0.13
0.01
14.23
Johnson & Johnson
Johnson & Johnson
22.92
22.92
0.89
9.85
0.24
0.08
0.03
29.09
Merck & Co. Inc.
Merck & Co. Inc.
145.42
145.42
0.1
8.0
0.05
0.1
0.02
15.94
Abbvie Inc
Abbvie Inc
49.06
49.06
0.45
11.25
0.56
0.08
0.04
4.54
Amgen Inc.
Amgen Inc.
45.02
45.02
2.39
19.44
0.73
0.05
0.03
9.36
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Gilead Sciences Inc.
Gilead Sciences Inc.
Buy
$84.5B
2.82%
188.5
1.77%
Eli Lilly And Company
Eli Lilly And Company
Buy
$732.9B
562.48%
113.57
17.08%
Johnson & Johnson
Johnson & Johnson
Hold
$371.3B
11.72%
22.92
44.92%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$331.5B
66.32%
145.42
3.76%
Abbvie Inc
Abbvie Inc
Buy
$290.2B
108.49%
49.06
11.02%
Amgen Inc.
Amgen Inc.
Buy
$168.8B
85.56%
45.02
12.74%

Institutional Holdings

  • BlackRock Inc

    9.85%

  • Vanguard Group Inc

    8.97%

  • Capital World Investors

    6.69%

  • Capital Research Global Investors

    4.78%

  • State Street Corporation

    4.77%

  • Dodge & Cox

    2.67%

Corporate Announcements

  • Gilead Sciences Inc. Dividends March,2024

    In the quarter ending March,2024. Gilead Sciences Inc. has declared dividend of $0.77

    Read More

Company Information

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.

Organization
Gilead Sciences Inc.
Employees
18000
CEO
Mr. Daniel P. O'Day
Industry
Health Technology

Discover More

FAQs